Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics

20260 citationsJournal Articlehybrid Open Access

Authors

NCT03145181 (phase 1, May 9, 2017); NCT04557098 (phase 2, September 21, 2020).

Good health and well-being

Published in: Targeted Oncology

Field-Weighted Citation Impact: 0.00